Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study.

ABSTRACT:

Purpose

No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess the efficacy and safety of bendamustine with dexamethasone (ben-dex) in patients with persistent or progressive AL amyloidosis after ≥ 1 prior therapy.

Methods

The trial enrolled 31 patients who received bendamustine on days 1 and 2 (100 mg/m² intravenously) with 40 mg of weekly dexamethasone in 28-day cycles until disease progression or up to 6 cycles after complete hematologic response. The primary objective was the rate of partial hematologic response (PR) or better.

Results

Patients received a median of 4 cycles (range, 2-12 cycle

SUBMITTER: Lentzsch S 

PROVIDER: S-EPMC7193746 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature